-

06:11:12 PM

ELOX Stock News

ELOX - Eloxx Pharmaceuticals Inc

01/25/23 8:00 AM

Nasdaq : ELOX

clinical triallow float

Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first

RHEA-AI

neutral

12/01/22 8:45 AM

Nasdaq : ELOX

low float

Eloxx Pharmaceuticals Announces Reverse Stock Split Effective

Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that

RHEA-AI

neutral

11/10/22 5:15 PM

Nasdaq : ELOX

low float

Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update

Started proof-of-concept Phase 2 clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations; topline results expected in the first half of 2023 On track to submit IND application for ZKN-013 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)

RHEA-AI

neutral

11/01/22 4:30 PM

Nasdaq : ELOX

clinical triallow float

Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the opening of clinical trial sites for its Phase 2

RHEA-AI

neutral

09/14/22 4:05 PM

Nasdaq : ELOX

clinical triallow float

Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no drug-related serious adverse events observed Evidence of activity for ELX-02 observed; efficacy signal potentially

RHEA-AI

neutral

08/15/22 8:00 AM

Nasdaq : ELOX

low float

Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update

Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected by the end of the third quarter of 2022 On track to initiate a proof-of-concept clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations in the

RHEA-AI

neutral

07/05/22 8:00 AM

Nasdaq : ELOX

managementlow float

Eloxx Pharmaceuticals Announces Changes to Board of Directors

Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra step down from the Eloxx board WATERTOWN, Mass., July 05, 2022

RHEA-AI

neutral

05/10/22 8:00 AM

Nasdaq : ELOX

low float

Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update

Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected at the end of the first half of 2022 Expanded development of ELX-02

RHEA-AI

neutral

03/31/22 7:00 AM

Nasdaq : ELOX

low float

Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update

Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program New development

RHEA-AI

positive

03/30/22 4:15 PM

Nasdaq : ELOX

low float

Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Strong rationale for development for Alport syndrome as ELOX-02 has demonstrated significant readthrough in COL4A5 nonsense mutations in preclinical studies and is preferentially transported to kidney Initiation of proof-of-concept clinical trial expected in second half of 2022; topline results

RHEA-AI

neutral

ELOX Data

IndustryResearch and Development in Biotechnology
Websitewww.eloxxpharma.com
CeoGregory Williams
Security nameEloxx Pharmaceuticals Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code8731
Tags
- Health Technology
- Biotechnology
Address950 Winter St
StateMassachusetts
CityWaltham
Zip02451-1424
CountryUS
Phone18589090749

About Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx's lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx's preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. Eloxx also has preclinical programs focused on kidney diseases including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders. Eloxx is headquartered in Waltham, MA, with operations in Rehovot, Israel and Morristown, NJ.